The UK and US have forged a major trade agreement that will preserve no import taxes on British pharmaceutical exports entering the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has pledged to increase expenditure on drugs through the public health system. This pledge guarantees that tariffs on these vital exports will stay at zero for a period of 36 months.
This deal comes after recent statements to significantly raise duties on branded pharmaceutical products, with potential rates mentioned reaching one hundred percent.
"This agreement between the United Kingdom reinforces the worldwide climate for cutting-edge drugs and brings long-overdue fairness to U.S.–U.K. medicine commerce," an announcement said.
Economic Significance
Medicines represent one of the the United Kingdom's most significant exports to the America, which is easily the biggest buyer for major companies like GSK and AstraZeneca.
Export figures reveal that in the 12 months leading up to September, the UK shipped pharmaceutical products valued at £11.1bn to the US. This amount made up a significant portion of total UK exports in that span.
"This agreement secures work, increases investment and sets the stage for the UK to emerge as a global hub for life sciences," a government official commented.
Detailed UK Commitments
The deal includes several notable changes from the UK:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it deems new therapies to be too expensive by 25%.
- Higher Drug Budget: There is a goal to raise total NHS spending on treatments from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount drug companies must return to the NHS to prevent overspending will be capped at fifteen percent. Previously, repayments topped twenty percent.
Recent Tensions
This agreement follows a ongoing tension between the sector and the ministers over drug pricing and approval rates.
This friction were exacerbated by claims that American customers were charged a premium for the identical medicines than consumers in the Britain and the EU.
In recent months, several significant pharmaceutical investments in the UK have been paused or scrapped, while multi-billion-dollar expansions have been pledged toward American operations.
The Science Minister publicly accepted that the NHS must invest a greater share on treatments, noting that its expenditure on drugs had decreased as a percentage of its overall budget over the last ten years.
